News Focus
News Focus
icon url

TampaTradr

08/30/16 6:14 PM

#271216 RE: biopharm #271214

What does this have to do with PPHM?
icon url

biopharm

11/08/16 5:20 PM

#278336 RE: biopharm #271214

Janssen/Johnson Johnson closing in with Dmitry Gabrilovich and realize how important PS Targeting truly is.... heck, I believe JnJ/Janssen have known for quite some time how big PS Targeting would become.
icon url

biopharm

04/12/17 5:11 PM

#294752 RE: biopharm #271214

"...anyhow... I wonder where Sue Siegel falls with GE now and...."

Amazing, Puzzle pieces continue to fall like dominoes and GE Ventures : Precision for Medicine (remember Tobias and keep moving up the food chain...)

Harry Glorikian
Managing Director, Strategy

Harry Glorikian joined Precision for Medicine as the Managing Director of Strategy and Personalized Medicine in December 2012 bringing world class advisory capabilities for life science and healthcare companies. Prior to Precision, Mr. Glorikian founded Scientia Advisors, a global management consulting firm specializing in strategy, operations, and pricing/reimbursement for major and emerging companies in healthcare, life sciences, pharma, biotechnology, and healthcare IT.

With 20 years of experience in the health care and life science industries, Mr. Glorikian has held senior management positions at Applied Bio Systems, Signet Laboratories, and X-Cell Laboratories, Inc. Mr. Glorikian has deep commercial background in diagnostics, molecular biology, proteomics, cellular biology, and biodefense. His unique understanding of technologies, operations, and strategy from both customer and industry player perspectives has shaped a sophisticated framework and proprietary analytic tools.

Mr. Glorikian has addressed the National Institutes of Health, Molecular Medicine Tri-Conference, World Theranostics Congress, and other audiences worldwide. He has authored numerous articles for industry publications, appeared on CBS Evening News and been quoted by Dow Jones, The Boston Globe, BioWorld Today, Los Angeles Times, London Independent, Medical Device Daily, Science Magazine, and many other media outlets.
Mr. Glorikian holds an MBA from Boston University and an undergraduate degree in Biology from San Francisco State University. He serves on many advisory boards and is an avid inventor who has several patents and patents pending in the U.S. and abroad.

https://www.slonepartners.com/leadership-series-interview-with-harry-glorikian-senior-executive-board-director-consultant-and-investor/

https://www.geventures.com/team#healthcare